Fig. 3: Chemoprotection by culture supernatants.
a Flow cytometry histograms of fluorescent labeling of live A549 cells with 102-5 anti-CLPTM1L primary and Alexafluor-488-conjugated secondary antibodies. b Relative viability (MTS) of A549 cells (vector control, or with CLPTM1L shRNA knockdown (shCLPTM1L) after exposure to cisplatin and culture supernatants from either vector control or CLPTM1L shRNA cells that were untreated or pre-treated with cisplatin (x axis). Error bars represent standard error of the mean. **p = 0.003, ***p = 0.0001. c Relative killing (live imaging cytotoxicity) of Panc1 pancreatic tumor cells after 24-h treatment with 100 nM gemcitabine and 72-h culture supernatants that were either untreated or pre-treated with 20 nM gemcitabine. Error bars represent standard error of the mean. d Relative killing by 40 µM carboplatin (live imaging cytotoxicity) of ovarian tumor cells treated with supernatants from control or 10 µM carboplatin-conditioned A2780 donor cells at 60 h post-carboplatin treatment. Supernatants in the 102-5 groups were pre-treated with 100 nM 102-5 anti-CLPTM1L overnight. Error bars represent standard error of the mean. *p < 0.05, **p < 0.005. e OVCAR5–CisR cells were treated with or without DMA or 102-5 Anti-CLPTM1L and western blotting was performed from the exosomes isolated from the conditioned media using indicated antibodies. f Results of cell viability assays performed on OVCAR5 cells treated with or without cisplatin that were untreated or pre-treated with culture supernatants of OVCAR5-CisR cells with or without DMA or 102-5 Anti-CLPTM1L (x axis). Error bars represent standard error of the mean.
